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Abstract
Background: Alpha-synuclein (asyn) has been shown to play an important role in the neuropathology of Parkinson’s
disease (PD). In the diseased brain, classic intraneuronal inclusions called Lewy bodies contain abnormal formations of
asyn protein which is mostly phosphorylated at serine 129 (pS129 asyn). This suggests that post-translational
modifications may play a role in the pathogenic process. To date, several uniplex assays have been developed in order
to quantify asyn not only in the brain but also in cerebrospinal fluid and blood samples in order to correlate asyn levels
to disease severity and progression. Notably, only four assays have been established to measure pS129 asyn specifically
and none provide simultaneous readout of the total and pS129 species. Therefore, we developed a sensitive
high-throughput duplex assay quantifying total and pS129 human asyn (h-asyn) in the same well hence improving
accuracy as well as saving time, consumables and samples.
Results: Using our newly established duplex assay we measured total and pS129 h-asyn in vitro showing that polo-like
kinase 2 (PLK2) can phosphorylate asyn up to 41 % in HEK293 cells and in vivo the same kinase phosphorylated h-asyn
up to 17 % in rat ventral midbrain neurons. Interestingly, no increase in phosphorylation was observed when PLK2 and
h-asyn were co-expressed in rat striatal neurons. Furthermore, using this assay we investigated h-asyn levels in brain
tissue samples from patients with PD as well as PD dementia and found significant differences in pS129 h-asyn levels
not only between disease tissue and healthy control samples but also between the two distinct disease states
especially in hippocampal tissue samples.
Conclusions: These results demonstrate that our duplex assay for simultaneous quantification is a useful tool
to study h-asyn phosphorylation events in biospecimens and will be helpful in studies investigating the precise causative
link between post-translational modification of h-asyn and PD pathology.
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Background
Parkinson’s disease (PD) is the second most common
neurodegenerative disorder affecting 1 % of people over
the age of 60 [1, 2]. Motor symptoms appear when 30–
50 % of dopaminergic neurons in the substantia nigra
(SN) and 70–80 % of dopaminergic terminals in the stri-
atum are lost [3, 4]. The cascade of pathological events
underlying the neurodegenerative process are unknown,
although a number of mechanisms such as impaired
protein clearance, oxidative stress, mitochondrial defects
and neuroinflammation have been suggested to play a
role [5–8]. The surviving neurons in the SN display
intracellular inclusions called Lewy bodies (LBs). In fact,
these inclusions are also found in cortex, amygdala,
locus coeruleus, olfactory bulb and the peripheral auto-
nomic system of patients suffering from PD [9, 10].
LBs were consistently found to contain a large amount
of accumulated alpha-synuclein (asyn) [11]. Analysis of
abnormally processed and aggregated asyn from patients
have revealed different post-translational modifications,
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including phosphorylation, nitration, ubiquitination and
C-terminal truncation of the protein [12–14]. Most of
the asyn accumulated in brains of patients is indeed
phosphorylated especially at serine 129 (pS129) [14, 15].
These findings lead to the development of independent
assays monitoring total asyn levels as well as its oligo-
meric and phosphorylated states, not only in brain tissue
but also in cerebrospinal fluid (CSF) and blood samples
[16–22]. Although assays for asyn as a wet biomarker
have been developed, particularly to quantify total asyn
levels for correlation with disease onset and progression,
only five assays have been developed for quantifying
pS129 asyn [15, 22–25]. Notably, none of the above
methods implemented a duplex assay platform to meas-
ure the total asyn and pS129 asyn in a single well. This
is particularly important not only to save samples, con-
sumables and time but also to measure asyn phosphoryl-
ation ratios more accurately especially when pS129 asyn
levels are very low.
Here, we describe a novel assay which allows simultan-
eous, sensitive and specific analysis of total and pS129
human asyn (h-asyn) species directly in the same well.
The assay provides a wide dynamic range permitting a sin-
gle run even when there are highly varying h-asyn loads
between samples. We provide validation by successfully
measuring total and pS129 h-asyn levels simultaneously
in human cell culture lysates, as well as in human and
humanized rat brain lysates.
Results
Specificity of antibodies for establishing human
alpha-synuclein AlphaLISA assays
We began our work towards developing an asyn select-
ive assay by examining the specificity of various com-
mercially available or custom generated antibodies to
asyn (Table 1). The initial evaluations were performed
using WB of tissue obtained from rats overexpressing h-
asyn, uninjected wild-type rats, or mouse tissue from
asyn knockout animals (Fig. 1a). Whereas the C-20
antibody (Santa Cruz, USA) recognized both the rat and
human asyn protein at the expected molecular weight of
17 kDa, LB509 (Covance, USA), syn204 (Cell Signaling,
USA), syn211 (Abcam, UK) and 4B12 (Covance, USA)
antibodies appeared to be specific to the human variant.
None of the five antibodies tested here showed strong
binding to another target as documented by the absence
of any strong bands on the respective lanes loaded with
asyn knockout tissue.
Next, we investigated the specificity of four antibodies to
pS129 asyn and any reactivity to the non-phosphorylated
variant. All antibodies tested at this step, namely pSyn#64
(WAKO, Japan; note that this antibody has since been dis-
continued), EP1536Y (Abcam, UK), MJF-R13 (Abcam, UK)
and 11A5 (Kind gift from Prothena Biosciences Inc.)
showed an expected band at approximately 17 kDa in the
pS129 h-asyn recombinant protein lane but lacked a corre-
sponding band for the S129A h-asyn recombinant protein,
a non-phosphorylatable asyn variant (Fig. 1b). Different
from the case above, two of the four antibodies tested here
(EP1536Y and MJF-R13) resulted in several strong bands in
the knockout tissue suggesting cross-reactivity to other
protein species. Only the custom synthesized 11A5
antibody had a favorable outcome with a strong specific
reactivity towards the pS129 asyn and only a single
non-specific band visible in the lane loaded with mouse
knockout tissue (Fig. 1b).
Selection of antibody pairs for the total and pS129
human alpha-synuclein specific AlphaLISA assays
The results above prompted us to take the next step in
the development of the AlphaLISA assay targeting the
h-asyn protein. For this purpose, we first tested the
signal to background (S/B) ratio for pairs of antibodies
towards detection of either total h-asyn or the pS129 h-
asyn protein (Table 2; section to the left). Four human
specific antibodies tested in the WB experiment were
included in the total h-asyn assay development step. The
results suggested that the 4B12 antibody worked best
Table 1 Antibodies (at 1 mg/ml) used for establishing AlphaLISA assays are listed below together with provider information
Clone Company Catalog # Host species Clonality Epitope Specific detection of
Human Rodent S129 phos
C-20 Santa Cruz sc-7011-RL rabbit polyclonal C-terminus yes yes no
LB509 Covance SIG-39725 mouse monoclonal 115–122 yes no no
asyn204 Cell Signaling 2647BF mouse monoclonal 087–111 yes no no
asyn211 Abcam ab80627 mouse monoclonal 121–125 yes no no
4B12 Covance SIG-39730 mouse monoclonal 103–108 yes no no
pSyn#64 WAKO 014-20281 mouse monoclonal 124–134 yes yes yes
EP1536Y Abcam ab173323 rabbit monoclonal yes yes yes
MJF-R13 Abcam ab176839 rabbit monoclonal yes yes yes
11A5 Prothena N/A mouse monoclonal 124–134 yes yes yes
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Fig. 1 Evaluation of antibodies in relation to species specificity and S129 phosphorylation state. The species specificity of asyn antibodies used in
the assay development (see Table 1) was tested using Western blot analysis by loading three different lysates – rat brain samples overexpressing
h-asyn (AAV hasyn rat), uninjected wild-type rats (uninj. WT rat) or asyn knockout mouse brain tissue (asyn k.o. mouse) (a). For lysates 50 μg of
protein was loaded. Actin is shown as a loading control. The specificity of antibodies for pS129 state was assessed using recombinant pS129 h-asyn
protein or S129A h-asyn protein. Two additional lanes were loaded with either rat brain lysate overexpressing h-asyn (AAV hasyn rat) or asyn knockout
mouse brain lysate (asyn k.o. mouse) to evaluate unspecific binding of antibodies on actual samples (b). For lysates 100 μg of protein per lane and for
recombinant h-asyn 2 ng of protein were loaded
Table 2 Antibody sensitivity in total (left) and pS129 h-asyn (right) assay is shown as signal to background ratios for each pair
AB’s conjugated to Europium Acceptor-beads (50 μg/ml)
LB509 syn211 syn204 4B12 EP1536Y MJF-R13 11A5
Biotinylated AB’s (5nM) LB509 0.7 N/A 16.4 84.8 N/A N/A N/A
syn211 N/A 2.5 9.2 233.5 N/A N/A N/A
syn204 174.1 100.2 1.0 1.1 15.3 101.8 21.2
4B12 440.9 576.3 1.1 0.9 35.8 114.6 704.2
N/A not analyzed
Bold data signifies most favorable signal to background ratios
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when conjugated to biotin and tested against the syn211
and LB509 antibodies coupled to Europium Acceptor-
beads (bold figures in Table 2). Notably, pairing the
same antibodies in the opposite orientation did not give
the same robust readout but were 2–5 fold lower in
signal-to-background ratio. Furthermore, as epitopes
used to raise the 4B12 and syn 204 antibodies have over-
lapping amino acid residues (especially at position 103
and 108; see Table 1), when these two antibodies were
paired, there was no detectable signal. Similarly, the epi-
tope for LB509 and syn211 antibodies share amino acid
residues 121 and 122, which are in fact different
between the rodent and human asyn protein. We have
not tested this combination as we anticipated the same
outcome as above. Next, we tested the three antibodies
specific for pS129 asyn after they were conjugated to the
Europium Acceptor-beads and paired with biotinylated
4B12 and syn204 (Table 2; section to the right). This test
revealed that the 4B12 – 11A5 antibody combination
was far superior (more than 6-fold higher signal-to-
background ratio) to other pairs and thus was selected
for further development.
Optimization of the AlphaLISA assay condition for uniplex
detection of total human alpha-synuclein or pS129 human
alpha-synuclein
The next step after selection of antibody pairs is the
hook-point evaluation, which refers to the optimal
concentration of the biotinylated antibody in the assay.
In the case of the total h-asyn assay, we performed this
analysis for both the LB509 and syn211 antibodies
conjugated to Acceptor-beads using the biotinylated
4B12 antibody at concentrations between 10 pM and
10 nM (Fig. 2a). We found that at a concentration of
1.0 nM of biotinylated 4B12 both antibody pairs
reached their maximum signal. As the signal from bio-
tinylated 4B12 and LB509 coupled Europium Acceptor-
bead pair was three times higher at all concentrations
tested we selected this pair as the best condition for
detecting total h-asyn.
To evaluate the dose-response characteristics for the
total h-asyn AlphaLISA assay, a standard curve was
established using either recombinant GST-tagged h-asyn
or recombinant mouse asyn (m-asyn) protein spiked into
wild-type rat brain lysate (Fig. 2b). The standard curve
for h-asyn displayed a typical sigmoid curve, while the
signal for m-asyn did not exceed the lower detection
limit (LDL). We identified that the linear dynamic range
of the h-asyn specific assay lies between 0.1 and 10 ng/
ml in-well concentration, while the estimated detection
limit is about 2.0 pg/ml and indicates a 3-times higher
sensitivity than what previous asyn assays have reported
[18–20]. Raw background counts from PBS solution
(106.0 ± 11.3) was indifferent from rodent brain lysate
readings (121.2 ± 16.9) demonstrating that the total asyn
assay has essentially no unspecific signal. Intra and inter
assay variations were calculated between four individual
standard curves using six concentrations on those curves
to validate the accuracy and variation between assay
runs (Fig. 2c, d) and 22 out of 24 measurements were
below 8.7 %, with two measurements (0.1 ng/ml) at 14.5
and 19.5 % (Fig. 2c, d).
The hook-point analysis for the pS129 h-asyn Alpha-
LISA assay showed that, while 3.0 nM of biotinylated
antibody provided the highest signal for the 4B12 –
11A5 antibody pair (Fig. 3a), using 1.0 nM of antibody
resulted in only 17.4 % of signal drop while saving 3-
times the amount of antibody. Dose-response charac-
teristics of the pS129 h-asyn assay was analyzed by
establishing standard curves using pS129 h-asyn and
S129A h-asyn recombinant protein spiked into asyn
knockout mouse brain lysate (Fig. 3b). The standard
curve for pS129 h-asyn displayed a typical sigmoidal
shape while signal for the S129A h-asyn between
1 pg/ml and 100 ng/ml concentrations remained
below the LDL. To ensure accurate calculations for
sensitivity and linear dynamic range of the pS129 h-asyn
assay, we measured the amount of phosphorylated h-asyn
using isoelectric focusing gels and determined 28 % of
our recombinant protein standard to be phosphorylated
(Additional file 1: Figure S1). All values reported for
pS129 h-asyn have been adjusted using this factor. The
linear dynamic range of the pS129 h-asyn assay for the
pS129 h-asyn protein is between 8 pg/ml and 3 ng/ml
in-well concentration with an LDL of 0.3 pg/ml, which
is about 30-times lower than a previously described
pS129 asyn assay [24]. Background signal for PBS solu-
tion (93.8 ± 10.8) was not distinguishable from rodent
brain lysate readings (114.9 ± 34.6) showing that the
pS129 h-asyn assay is free from interfering non-specific
signal. Intra and inter assay variations were again calcu-
lated using six different concentrations on four indi-
vidually run standard curves and was lower than 8.7 %
for all measurements (Fig. 3c, d).
Feasibility and performance assessment of duplex
AlphaLISA assay for quantification of total and pS129
human alpha-synuclein in a single well
The challenge in designing a duplex detection method
in an antibody based quantitative assay for a single pro-
tein target in two confirmations, as opposed to one
where two separate protein targets are measured in the
same well, is two-fold: First, a fraction of the target pro-
tein is expected to be labeled with two antibodies linked
to Acceptor-beads and a third antibody-biotin complex
to anchor the Donor-bead to the same target (Additional
file 2: Figure S2). Thus, the assay validation steps have to
include assessment of steric hindrance at the binding
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site of either Acceptor-bead coupled antibody by the
other. Second, as the two Acceptor (reporter) beads rely
on the same Donor (activator) bead but only one of
them is read at a time, the sequence of acquisition of the
signal needs to be considered.
To this end, our first task in designing the duplex
assay for h-asyn and its post-translationally modified
pS129 species was to evaluate the characteristics of
the Terbium Acceptor-beads compared to Europium
Acceptor-beads for the LB509 and 11A5 antibodies. Signal
characteristics of both Acceptor-beads were tested by com-
bining biotinylated 4B12 antibody with LB509 antibody
coupled to either Europium or Terbium Acceptor-beads
separately and by using purified protein in a dose-response
curve. Overall Terbium signal was about 100-fold lower in
all measurements including blanks as compared with the
Europium signal under identical conditions. As the back-
ground signal in this assay was also significantly lower, the
S/B ratio of the standard curves obtained using Terbium
beads were only marginally affected as compared with the
Europium Acceptor-beads (Fig. 4a). The same setup was
used for the 4B12 and 11A5 antibody pair (Fig. 4b). In the
latter case the difference in S/B between Europium and
Terbium Acceptor-beads was more pronounced. Because
of this phenomenon and the fact that there will always be a
higher quantity of total h-asyn compared to pS129 h-asyn,
Fig. 2 Characterization of total human alpha-synuclein AlphaLISA. The hook-point analysis was evaluated for serial dilutions of biotinylated 4B12 in combin-
ation with Europium Acceptor-beads coupled to either LB509 (LB509-Eu) or syn211 (syn211-Eu) using a 19 ng/ml of recombinant GST-tagged h-
asyn protein diluted in 10 μg/ml of Tris wild-type rat brain lysate (a). Arrow indicates the highest signal obtained and therefore optimal 4B12-
biotin concentration to use. Standard curve was established for biotinylated 4B12 and Europium Acceptor-bead coupled LB509 by serial dilu-
tion of either GST-tagged h-asyn or mouse asyn (m-asyn) protein spiked in Tris brain lysate obtained from a naïve rat (10 μg/ml) (b). The lower
detection limit (LDL) was 3.7 pg/ml and is indicated by a dashed line. Intra assay variation was calculated based on two standard curves which
were measured on the same day but on separate plates (c). Inter assay variation data was calculated based on two pairs of standard curves per-
formed on separate days (d). AU arbitrary units
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we chose to use Terbium Acceptor-beads coupled to
LB509 and conjugated the 11A5 antibody to Europium
Acceptor-beads. We concluded also that reading the Ter-
bium signal first followed by the Europium signal next was
the best protocol.
The epitopes of the two Acceptor-bead coupled anti-
bodies in our assay were very close (see Table 1 for details).
Therefore, we explored whether the steric hindrance af-
fected the results by comparing the signal intensity of uni-
plex and duplex condition for each Acceptor-bead coupled
antibody (see Additional file 3: Figure S3 for graphical illus-
tration of the principle). When the signal is the same for
both conditions, no hindrance occurs when both antibodies
are binding to the analyte (Additional file 3: Figure S3).
When the signal in the duplex condition is lower than in
the uniplex condition, the other Acceptor-bead coupled
antibody complex is sterically hindering the binding (Add-
itional file 3: Figure S3). We found that the signal obtained
from Terbium Acceptor-bead coupled LB509 (LB509-Tb)
[Fig. 4c; where signal detected from the Terbium filter
(Resorufine/Amplex Red FP535) for both conditions is dis-
played on the left, while the signal detected via the Euro-
pium filter (Europium 615 nm) of the same wells are
shown on the right] was not affected due to presence of the
11A5-coupled Europium Acceptor-bead (11A5-Eu). Simi-
larly, the signal obtained from the 11A5-Eu Acceptor-beads
were not influenced by the addition of Acceptor-beads
coupled to the LB509 antibody (Fig. 4d).
Fig. 3 Characterization of S129 phosphorylated human alpha-synuclein specific AlphaLISA. The hook-point analysis was evaluated for biotinylated
4B12 and Europium Acceptor-bead conjugated 11A5 (a). Pair was tested using 14 ng/ml of pS129 h-asyn protein diluted in 10 μg/ml of Tris brain
lysate obtained from an asyn knockout mouse. Arrow indicates the optimal biotinylated antibody concentration to use. Standard curve was
established for biotinylated 4B12 and Europium Acceptor-bead coupled 11A5 by serial dilution of either pS129 h-asyn or S129A h-asyn
protein spiked in wild-type rodent brain lysate (10 μg/ml) (b). The lower detection limit (LDL) was 1.1 pg/ml and is indicated by a dashed
line. Intra assay variation was calculated based on two standard curves which were measured on the same day but on separate plates (c) while the
inter assay variation was calculated based on two pairs of standard curves performed on separate days (d). AU arbitrary units
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Fig. 4 Evaluation of the duplex AlphaLISA performance. Assessment of the Acceptor-bead performance and comparison between Europium and
Terbium based beads was carried out once for both the LB509 (a) and the 11A5 (b) antibodies. In both instances the biotinylated 4B12 antibody
was used and signal to background ratio calculated against serial dilutions of h-asyn proteins spiked in naïve rat brain lysate. Presence of
any hindrance of Acceptor-bead coupled antibodies against each other was assessed for LB509-Terbium (c) and 11A5-Europium beads (d).
Cross-talk between the channels was assessed using the Resorufine/Amplex Red FP535 Terbium filter (e) and the Europium 615 filter (f).
For these experiments the relevant analyte, Acceptor- and Donor-bead information is given under the x-axis. Both the hindrance of Acceptor-bead coupled
antibodies and the channel cross talk were run twice. See Additional file 2: Figure S2 for a theoretical explanation of the phenomena. AU arbitrary units
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Next, to ensure that the signals measured for Terbium
and Europium were indeed not influenced by one another,
we tested their respective filters for signal bleed-through.
Bleed-through can result when Europium and Terbium
Acceptor-beads emit signal at the same time but the filter
used to separate out the signal of one specific Acceptor-
bead also lets light pass from the second Acceptor-bead
(see Additional file 3: Figure S3 for graphical representation
of the principle). We measured Terbium and Europium sig-
nal of two different conditions where one condition had no
analyte and no second Acceptor-bead (background noise)
while in the second condition analyte was added. The sig-
nals resulting from those measurements were used to cal-
culate the percent of bleed-through. The bleed-through for
the Terbium filter was estimated at 2.4 % (Fig. 4e), while
the bleed-through of the Europium filter was estimated to
be 0.9 % (Fig. 4f). All measurements reported for the steric
hindrance in this section as well as all other data referring
to the duplex assay is corrected for filter bleed-through
based on these estimates.
Hook-point was established for the duplex assay where
Europium and Terbium signal was measured in the
same well. Optimal biotinylated 4B12 concentration was
found to be unchanged at 1.0 nM (Fig. 5a). To ensure
that the Donor-beads added to the wells were suffi-
cient to provide enough oxygen singlets for two
Acceptor-beads, a serial dilution of Donor-beads was
made ranging from 6 to 40 μg/ml in the well. No
change in signal intensity for either Acceptor-bead
was seen (Additional file 4: Figure S4). When com-
paring the signal intensity of h-asyn and pS129 h-asyn
standard curves both measured using the total h-asyn
assay (Terbium channel), no difference in signal inten-
sity or curve shape was observed (Fig. 5b). While the
LDL of the pS129 h-asyn duplex assay was similar to
the LDL obtained for the pS129 h-asyn uniplex assay,
we observed a 235-fold increase (from 2 to 470 pg/ml)
when comparing the LDL for uniplex and duplex total
h-asyn assays.
Intra- and inter-assay variations were calculated be-
tween six individual standard curves performed on three
different days using 6 to 7 concentrations on those
curves to validate the accuracy and variation between
runs. For the total h-asyn assay, average intra assay vari-
ation did not exceed 23 % while the average inter assay
variation was lower than 22.8 % (Fig. 5c, e). Values were
notably higher than what was obtained with the uniplex
total h-asyn assay. For the pS129 h-asyn assay, average
intra-assay variation did not exceed 13.7 % while the
average inter assay variation was lower than 14.5 %
(Fig. 5d, f ). Z’ values were calculated using 12 replicates
of naïve rat brain lysate (blank) or lysate spiked with
pS129 h-asyn protein. Z’ values for the total h-asyn and
the pS129 h-asyn assay was 0.81 and 0.84, respectively.
Quantification of pS129 and total human alpha-synuclein in
HEK293 cells co-expressing h-asyn and polo-like kinase 2
To further validate the newly established duplexing assay
we co-transfected HEK293 cells with a single vector
construct co-expressing h-asyn and PLK2 under the hu-
man CMV and murine CMV promoters, respectively (n
= 6 per group). PLKs have been shown previously to
highly phosphorylate asyn specifically at position 129
[26]. As controls, a PLK2 kinase dead-mutant (mPLK2)
and non-phosphorylatable S129G h-asyn were used. All
proteins were also expressed in combination with YFP
or mCherry instead of h-asyn or PLK2, respectively.
Note, HEK293 cells produce a substantial amount of en-
dogenous h-asyn as well as pS129 h-asyn (1.2 % of total
h-asyn), which can be measured using the duplexing
assay (Fig. 6). Expression of PLK2 without h-asyn showed
an increase in pS129 h-asyn by 4.8-fold due to PLK2 activ-
ity compared to single mPLK2 expression but did not
phosphorylate h-asyn efficiently/completely. Single h-asyn
also resulted in a smaller yet significant increase of pS129
h-asyn compared to expression of S129G h-asyn alone
since more phosphorylatable h-asyn is available for en-
dogenous kinases. Expressing S129G h-asyn in com-
bination with PLK2 resulted in an increase in pS129
h-asyn by 5.2-fold due to PLK2 activity on endogenous
h-asyn but was considerably smaller (11.7-fold) than
in the h-asyn + PLK2 group. When h-asyn is co-expressed
with PLK2, pS129 h-asyn levels increased as expected
when compared to h-asyn expressed together with
mPLK2 (32.4-fold). No difference in total h-asyn levels
was observed.
Evaluation of human alpha-synuclein phosphorylation
efficiency in the rat brain by viral vector co-expression
of h-asyn and polo-like kinase 2
To investigate the effects and efficiency of PLK2 in-
duced pS129 of h-asyn in vivo we used a 1:1 mix of re-
combinant adeno-associated viral vector serotype 6
(rAAV6) expressing h-asyn together with rAAV6 ex-
pressing either PLK2 or mPLK2. Vector mixes were
injected into the SN (Fig. 7a–o) or striatum (Fig. 7p–
d’) of rats to examine h-asyn handling and phosphoryl-
ation differences in two different cell types. Targeting
and expression were assessed two weeks after injection
(n = 4 per group) by staining coronal ventral midbrain
and striatal sections using the h-asyn specific antibody
syn211 (Fig. 7a–c, p–r). H-asyn staining showed a good
coverage and transduction of ventral midbrain neurons
(Fig. 7b, c) while striatum was covered partially (Fig. 7q, r).
Presence or absence of cell death was visually assessed
first using two cell type specific stainings for dopaminergic
neurons (Fig. 7d–f ) and striatal neurons (Fig. 7s–u), and
cresyl violet staining of adjacent sections (Fig. 7g–i, v–x).
Initial visual inspection suggested a partial reduction
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Fig. 5 Characterization of total and phosphorylated S129 human alpha-synuclein duplex assay. The hook-point for biotinylated 4B12 antibody was
determined simultaneously in a mix of Europium Acceptor-bead coupled 11A5 antibody and Terbium Acceptor-bead coupled LB509 antibody
(a). Arrows indicate optimal 4B12 concentrations for both Acceptor-bead variants. Equivalency of the signal obtained in the total h-asyn assay
was demonstrated for pS129 h-asyn and h-asyn proteins in the duplex assay in two consecutive experiments and data plotted in panel (b). All
protein standards were spiked in naïve rat brain lysate. Lower detection limit (LDL) was 450 pg/ml and is indicated with a dashed line. Intra
assay variation was calculated based on three standard curves which were measured on the same day but on separate plates for each emission signal
separately (c and d). Inter assay variation data was calculated based on six pairs of standard curves performed on separate days (e and f).
AU arbitrary units
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of dopaminergic neurons on the injected compared to
uninjected side in the SN (Fig. 7d–i). As we have
chosen a low vector titer and a short expression time,
we did not anticipate any major cell loss and found
no significant difference between the PLK2 and
mPLK2 group (p = 0.11). In striatal sections, no ap-
parent cell death was found in either experimental
group when compared to a naïve brain (Fig. 7s–x)
nor was there any significant change found between
the PLK2 and mPLK2 group (p = 0.49). To confirm
double transduction of single neurons, sections were
co-stained for h-asyn and PLK2 (Fig. 7j–o, y–d’).
Staining for h-asyn showed similar localization of the
protein in nigral (Fig. 7j, m) and striatal (Fig. 7y, b’)
neurons. PLK2 (Fig. 7k, z) or mPLK2 (Fig. 7n, c’)
staining co-localized in both brain areas with that of
h-asyn (Fig. 7l, o, a’, d’) showing that both PLK2 pro-
teins and h-asyn are co-expressed in the same tar-
geted cells.
To quantify total and pS129 h-asyn levels of trans-
duced rat brain areas, fresh frozen tissue (n = 6 per
group) taken two weeks after injection was lysed using
first 1 % Triton followed by 1 % SDS lysis buffer sequen-
tially and samples of each fraction and region were ana-
lyzed using the newly established duplex assay (Fig. 8).
No differences in total h-asyn levels were observed in
ventral midbrain samples for both Triton and SDS
fractions (Fig. 8a, d) nor in fractions of striatal tissue con-
taining the terminals of transduced nigral neurons (Fig. 8b,
e). An increase of pS129 h-asyn levels of 2.7-fold was
found in ventral midbrain neurons expressing PLK2 when
compared to cells expressing mPLK2 (Fig. 8a). This in-
crease was not only visible in the Triton but also in the
SDS fraction (Fig. 8d). No increase of pS129 h-asyn levels
was found in terminals of nigral neurons (Fig. 8b, e). The
levels of h-asyn in striatal neurons were unchanged be-
tween groups and fractions (Fig. 8c, f ). Interestingly, stri-
atal neurons expressing both h-asyn and PLK2 did not
show an increase of pS129 h-asyn levels suggesting a dif-
ferent regulatory mechanism of h-asyn phosphorylation
or PLK2 activity between striatal and ventral midbrain
neurons.
Alterations in phosphorylation state of human
alpha-synuclein (h-asyn) in Parkinson’s disease (PD)
patients with and without dementia
First, we set out to evaluate the sample reproducibility
for the AlphaLISA duplexing assay. To do so, we lysed
frontal cortex tissue samples from healthy controls (n = 16)
using buffer containing 1 % Triton and measured total as
well as pS129 h-asyn as five independent measurements in
each sample carried out over several days. We found that
the variation in the total and pS129 h-asyn values were very
similar despite 2–3 orders of magnitude differences in their
quantities and were below 25 % in all but 1 measurement
(Additional file 5: Figure S5). Furthermore, when consider-
ing the ratio between the pS129 and total h-asyn, we found
that the variation of these estimates were even lower (76
out 80 estimates with <10 %) (Additional file 5: Figure S5).
We then continued to investigate the accumulation of
pS129 h-asyn in human brain tissue samples from patients
diagnosed with either PD alone or PD with dementia
(PDD) as well as in samples obtained from healthy controls
(Ctrl) (n = 8 per group). We acquired four different brain
areas for each case – putamen, hippocampus, frontal cortex
and motor cortex – which were sequentially lysed first with
buffer containing 1 % Triton followed by 1 % SDS contain-
ing buffer. Both fractions were analyzed using the newly
validated duplex AlphaLISA assay (Fig. 9). When looking at
the triton fraction, no difference was observed for total h-
asyn but pS129 h-asyn levels were significantly increased
for PD patients in both cortices and for PDD patients in
hippocampus and motor cortex when compared to Ctrl
cases (Fig. 9a–d). Evaluation of SDS soluble h-asyn showed
a significant accumulation of total h-asyn levels in the
putamen and frontal cortex for PD cases as well as in the
frontal cortex for PDD cases when compared to Ctrl sam-
ples (Fig. 9e, g). Additionally, in all four brain areas a signifi-
cant increase of pS129 h-asyn quantities was detected for
both PD and PDD cases compared to Ctrl cases (Fig. 9e–
Fig. 6 S129 specific phosphorylation of human alpha-synuclein using
PLK2 in vitro. HEK293 cells were transfected with dual expression
plasmids coding for h-asyn or S129A h-asyn as well as PLK2 or
the kinase dead mutant (mPLK2) (n = 6 per group; about 3 μg of
protein loaded). Levels of total (open) and pS129 h-asyn (filled)
of whole cell lysates were measured using the newly established
AlphaLISA duplex assay and are presented in overlapping bars.
Percentages of pS129 h-asyn to total h-asyn are indicated in
the bottom of respective bars. **p <0.01; ##p <0.01; two-tailed
Mann-Whitney test; Error bars indicate SEM
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h). Notably, pS129 h-asyn levels in hippocampal samples
were substantially increased in PDD cases when compared
to PD cases (Fig. 9f) signifying the importance of the hippo-
campal pathology in demented PD patients.
Discussion
Several asyn specific assays have been developed to
measure levels of total asyn protein and its modified
variants in brain tissue, CSF and plasma samples with
the goal to find a wet biomarker for PD and other synu-
cleinopathies [17, 18, 21, 27, 28]. As pS129 asyn com-
prises a large part of asyn found in inclusions [14], it has
been of interest to further measure pS129 asyn levels in
various samples collected from patients. However, so far
only four studies have quantified the levels of pS129
asyn in brain tissue [15, 25, 29, 30] while five studies
Fig. 7 Transgene expression after rAAV injection in the rat substantia nigra and striatum. Adeno-associated viral vectors expressing either PLK2 or
mPLK2 were mixed at a 1:1 ratio with a vector encoding for h-asyn and injected into rat substantia nigra or striatum (n = 4 per group). Two weeks
after transduction, gene expression was visualized using the asyn211 antibody on sections from ventral midbrain (a–c) or striatum (p–r). Panels
(d–f) and (s–u) show vesicular monoamine transporter 2 (VMAT2) stainings for dopaminergic nigral neurons and dopamine- and cAMP-regulated
neuronal phosphoprotein 32 (DARPP32) stainings for striatal neurons from the two targeted structures, respectively. Cresyl violet stainings
from adjacent sections are shown in (g–i) for the ventral midbrain and in (v–x) for the striatum. High magnification confocal images of
transduced cells illustrate co-expression of asyn (green) and PLK2 (magenta) transgenes in nigral (i–o) and striatal neurons (y–d’). Scale bar in (a) and
(p) is 0.4 mm and applies to (a–c) and (p–r), in (g) and (v) are 100 μm and apply to (d–i) and (s–x), respectively, and in (m) is 10 μm
and applies to (i–o) and (y–d)'
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investigated CSF and blood samples [22–24, 31–33].
Notably, none are duplexed to report total and pS129
asyn simultaneously in the same sample.
By using the newly developed Terbium Acceptor-beads
(PerkinElmer, USA), we developed a specific and sensitive
duplex AlphaLISA assay to quantify total and pS129 h-
Fig. 8 Assessment of S129 phosphorylated human alpha-synuclein in rat brain tissue. Quantification of pS129 h-asyn species after overexpression
from rAAV6 vectors in the substantia nigra (a, b, d, e) or striatum (c, f). Tissue pieces (n = 6 per group) were processed sequentially with 1 % Triton
(about 300 ng for striatal and 90 ng for VM samples of protein loaded) (a–c) followed by 1 % SDS (about 600 ng of protein loaded) (d–f) containing
lysis buffer. Total (open) and pS129 (filled) h-asyn levels are presented in overlapping bars. Numbers inside the bars show the percent of pS129 to total
h-asyn. **p <0.01; two-tailed Mann-Whitney test; Error bars indicate SEM
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asyn in the same well (Additional file 2: Figure S2),
thereby providing a highly accurate phosphorylation ratio.
This is especially important since pS129 asyn levels are
under normal conditions lower than 0.4 %. Our duplex
assay proved useful not only in cell culture lysates but also
in human and humanized rat brain tissue samples. Even
when as little as 0.2 % of total h-asyn was phosphorylated
at S129, the dynamic range of the duplexing assay was suf-
ficiently wide to obtain both measurements with a single
dilution and run. The assay protocol requires no washing
and can be completed within 90 min of incubation time,
which is therefore ideal for high throughput screenings,
allows for cost efficient runs and uses lower amounts of
sample material than running separate uniplex assays.
Each (uniplex) component of the assay developed here
has a matching or improved sensitivity compared to pre-
viously described results. Naturally, in combining two
uniplex assays into one duplex assay, we expected a de-
crease in sensitivity of one of the assays due to the use
of the Terbium as opposed to the Europium Acceptor-
beads. In order to minimize and eliminate any signifi-
cance of the S/B disadvantages due to the difference in
signal intensities emitted by the two beads, we imple-
mented the weaker of the two signals (Terbium beads)
for the more abundant of the two species, namely the
total h-asyn protein. Nevertheless, in future studies, this
S/B disadvantage could be improved by, e.g., implemen-
tation of an enhanced filter/detector system to better
Fig. 9 Assessment of S129 phosphorylated human alpha-synuclein species in post mortem brain tissue. Frozen human brain tissue samples were
received from healthy controls (Ctrl), patients diagnosed with Parkinson’s disease (PD) or Parkinson’s disease with dementia (PDD) (n = 8 per group).
Four brain regions were analyzed: putamen (a, e), hippocampus (b, f), frontal cortex (c, g) and motor cortex (d, h). Tissue was sequentially lysed first
using 1 % Triton (about 100 ng of protein loaded) (a–d) followed by 1 % SDS containing lysis buffer (about 2 μg of protein loaded) (e–h). Total
(open) and pS129 (filled) h-asyn levels are presented in overlapping bars. Numbers inside the bars show the percent of pS129 to total h-asyn.
*p <0.05; **p <0.01; #p <0.05; one-way ANOVA followed by a Tukey’s HSD test or Kruskal-Wallis followed by a Dunn’s multiple comparisons
test; Error bars indicate SEM
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channel and amplify the low signal generated by the
Terbium Acceptor-beads and/or by a development of a
version of the Terbium Acceptor-beads with superior
signal characteristics. This would not only result in lower
standard deviation values between replicates and therefore
more accurate estimations but also a lower detection limit
and wider linear response range in the assay.
As already noted by others [20, 34], the quality (and
therefore the estimated quantity) of recombinant asyn
proteins used as standards in an assay is important espe-
cially as different production batches are used between
laboratories and sometimes also within one laboratory.
Bidinosti and colleagues reported up to 3-fold differ-
ences in assay signal depending on the protein standards
used [20]. Standards generated by phosphorylating re-
combinant h-asyn protein in vitro using PLK2, as is
done here, have been reported to result in incomplete
phosphorylation of the protein at the S129 residue [26],
potentially with batch to batch variations, and present
the risk for incorrectly calculated phosphorylation ratios.
Therefore, a quality control step such as isoelectric fo-
cusing gel or alternatively mass spectrometrical analysis
should be applied in order to evaluate phosphorylation
efficiency of each recombinant protein batch. A stan-
dardized and careful estimation of protein concentration
and phosphorylation would allow more reproducible re-
sults between batches used in a given assay platform and
various types of assays targeting the same protein.
Previous studies have suggested that PLK2 not only
phosphorylates asyn [26, 30, 35] but also targets it for
autophagosomal degradation [36]. Here, we could readily
demonstrate that PLK2 can phosphorylate h-asyn in
co-transfected HEK293 cells. Although, we found no
evidence for reduction in total h-asyn levels in this
cell-based in vitro assay nor was this apparent in rat
brain tissue co-expressing h-asyn and PLK2 proteins.
Nevertheless, we found an elevation of pS129 h-asyn
levels from 6.1 to 16.9 % (2.8-fold) in rat ventral mid-
brain neurons caused by the co-expression of PLK2.
Furthermore, we determined the baseline pS129 rat
asyn (r-asyn) level in the Triton fraction of the ven-
tral midbrain samples to be 0.007 % (Additional file
6: Figure S6) suggesting that the transgenic h-asyn is
phosphorylated about 890 times more than the en-
dogenously expressed r-asyn. Notably, our estimations
of baseline pS129 to total r-asyn ratio is lower than
what Bergeron and colleagues reported [30]. Never-
theless, the large difference between the proportions
of endogenous pS129 r-asyn versus transgenic pS129
h-asyn protein in vivo suggests an alternative handling of
the h-asyn protein. This difference is unlikely to be due to
excessive overexpression of asyn per se as the transgenic
human protein concentration in the tissue was 233 ng/mg
protein, while the endogenous rat protein levels were
estimated at an average of 706 ng/mg protein (Additional
file 6: Figure S6).
In the striatal tissue, the endogenous r-asyn levels
(1843 ng/mg protein) are about 2.6-fold higher than in
the ventral midbrain with about 0.013 % being phos-
phorylated at S129. AAV vector mediated expression of
h-asyn in the striatum resulted in an additional 336 ng/
mg of asyn protein and its phosphorylated fraction was
found to be 3.1 %. Taken together, these observations
suggest that the two cell populations in striatum and
midbrain respond to the transgenically expressed h-asyn
in a similar way, namely the hyper-phosphorylation of h-
asyn. Interestingly, the co-expression of PLK2 in the stri-
atal neurons did not result in an increase in the pS129
h-asyn portion, nor were there any indications that the
total h-asyn levels in this group was reduced, making it
unlikely for differential degradation of the pS129 species
in the striatal neurons to account for this difference.
Taking into consideration that most of the asyn found in
LBs is phosphorylated at the S129 residue and that this
post-translational modification is suggested to promote
the formation of oligomeric species in vitro [14, 15], our
findings could provide evidence as to why certain cell
types such as dopaminergic neurons are more vulnerable
and affected earlier by asyn toxicity than cell types
located in the striatum or cortical areas [37].
Another striking observation here was that the propor-
tion of phosphorylated h-asyn in the striatal axon termi-
nals of the nigrostriatal neurons was lower than in the
cell bodies located in the midbrain (0.6 % versus 6.1 %).
Although the co-expression of PLK2 in nigral neurons
resulted in readily detectable increases in the portion of
pS129 h-asyn, there was no measurable effect at the level
of their terminals. This was true despite the fact that
transportation of the transgenic protein from the cell
bodies to the terminals was rather efficient. These obser-
vations could suggest either a selective transport of the
non-phosphorylated h-asyn to the terminals, or alterna-
tively an effective de-phosphorylation once the protein
leaves the cell body; entering the transport system. The
former scenario would argue that the two pools of asyn
proteins have differential functions in the cells (e.g.,
non-phosphorylated asyn is selectively involved in vesicle
pool regulation and SNARE complex formation [38, 39]);
alternatively the second scenario could point to differential
phosphatase activities in the ventral midbrain and the
striatum, although the precise composition and relative
activity of phosphatases that act on pS129 asyn are not
well studied.
Although the total amount of transgenically expressed
h-asyn was about 33 % of endogenous asyn levels in the
Triton fraction of the midbrain tissue, we found nearly
70-fold increase in the SDS fraction in the same samples
(for endogenous r-asyn measurements see Additional
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file 6: Figure S6). Notably this striking difference was
detected not only in the total asyn protein but also in
the pS129 species, although the great majority of all
asyn in the SDS fraction was not phosphorylated. On
the other hand, the contribution of h-asyn in the striatal
axon terminals in the Triton insoluble fraction was com-
parable to the endogenous r-asyn. Since animals in this ex-
periment were killed 2 weeks after injection, these findings
could suggest evidence of early formation of h-asyn species
resistant to Triton treatment that is independent of phos-
phorylation at serine 129 residue. An alternative explan-
ation that is not mutually exclusive with the above scenario
is that h-asyn is translocated to the nucleus and thus ap-
pears in the SDS extracted fraction. In fact, when samples
are lysed sequentially first in Triton and then in SDS con-
taining buffers, as done here, proteins located in the nu-
cleus such as Histone3 are released to the supernatant in
the SDS fraction since Triton cannot break the nuclear
membrane. While this increase was evident in ventral mid-
brain neurons, a similar increase in Triton insoluble h-asyn
was not observed in striatal neurons – i.e., the levels of
h-asyn in the SDS fraction were comparable to those of en-
dogenous r-asyn. Notably, independent of the source (com-
partment) of the SDS extracted asyn protein, it appears
from our observations that even a robust increase in the
pS129 post translationally modified species has no effect
on the relative abundance of this protein in the Triton sol-
uble and insoluble asyn pool in the tissue. In other words,
addition of the active PLK2 enzyme increases the pS129-
to-total asyn ratio by about 3-fold in both fractions.
Total amounts of Triton soluble asyn in naïve rats was
comparable to levels in post-mortem human brain tis-
sue, while the SDS fraction showed higher amounts of
total asyn in humans compared to rats. Although the
same relationship was true for the fraction of asyn that
is phosphorylated in the rat and human brain, respect-
ively, when the h-asyn is expressed in the rat brain, this
protein species was phosphorylated to a higher level
than either of the endogenous species. In human post-
mortem brain tissue, we found no change in total or h-
asyn levels in the Triton fraction between healthy control
and disease cases and in 4 brain areas studied here. Simi-
larly, pS129 asyn ratio was between 0.2 and 0.3 % of the
total asyn, where only small differences appeared in PD
and PDD cases against the controls, with no clear distinc-
tion between two disease states. The findings in the SDS
soluble fraction were fundamentally different: First, the
pS129 species was over-represented in this fraction by 20
to 100-fold in the PD/PDD cases. This increase is in
agreement with previous studies [40, 41] and reflects the
pathological features of a diseased brain. Secondly, a clear
difference between two disease groups could be seen in
the hippocampal area, where the pS129 species were
much more abundant in the PDD brains. Notably, analysis
in the putaminal tissue did not reveal a difference and in
other cortical areas (motor and frontal cortices) the dif-
ferences were smaller and did not reach significance in
this dataset. This result corroborates our previous find-
ing where a specific increase in the number of h-asyn
positive Lewy neurites was found in hippocampal region
on histological specimens of PDD cases when compared
to PD cases [42].
Conclusion
In summary, we have established a novel assay which sim-
ultaneously measures total and pS129 h-asyn levels and
therefore increases the accuracy of the quantified phos-
phorylation ratio. Using this assay, we examined the extent
of PLK2 enzyme activity on asyn in vitro and in vivo and
showed that PLK2 increases pS129 h-asyn levels in
HEK293 cells. Notably, when rat brain cells were trans-
duced to co-express h-asyn and PLK2, pS129 h-asyn quan-
tities increased in the ventral midbrain but not in the
striatum. Furthermore, we measured the asyn phosphoryl-
ation state in post-mortem brain areas of PD and PDD
cases allowing us to see a clear increase in pS129 h-asyn
signal in the hippocampus when PD patients develop de-
mentia. Future studies will need to focus on the simultan-
eous measurement of total and pS129 h-asyn levels in
multiple biospecimens from the same patient (CSF and/or
plasma as well as brain tissue) and to correlate those results
to brain asyn levels and disease progression and severity.
Methods
The AlphaLISA® platform
The assay was developed by PerkinElmer as a no-wash
assay for a highly sensitive, high throughput, widely dy-
namic and robust detection of analytes in biological sam-
ples [43]. It offers several advantages over conventional
enzyme-linked immunosorbent assays (ELISAs). The sig-
nal of this bead-based immunoassay is based on the lumi-
nescent proximity principle using oxygen-channeling
chemistry. In the most commonly used format, the
Donor-bead is coupled via streptavidin-biotin link to the
first antibody while the second antibody is directly
coupled to the Acceptor-bead (Additional file 7: Figure
S7). Binding of both antibodies to the same analyte brings
the two beads into desired proximity. Excitation of Donor-
beads at 680 nm creates singlet oxygens triggering a cas-
cade of chemical events in Acceptor-beads less than
200 nm away leading to a chemiluminescent emission.
The assay is performed with a simple “mix-and measure”
protocol shown in Additional file 7: Figure S7.
Establishment of the human alpha-synuclein specific
assays
Antibodies were obtained from commercial suppliers or
as a gift (as indicated in Table 1) either as manufactured
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or custom orders to ensure antibodies were at 1 mg/ml
in only PBS (Thermo Fisher Scientific, USA) with no
BSA or azide present in the solution.
Biotinylation of antibodies: 2 mg/ml NHS-ChromaLink-
biotin (SoluLink, USA) in PBS pH 7.4 was added to each
antibody solution (BSA, glycerol and azide free) at a 30:1
molar ratio. The volume was adjusted to 100 μl with PBS
pH 7.4. After incubating for 2 h at 23 °C in the dark, the
antibody-biotin solutions were filtered through Zeba spin
columns (Thermo Scientific, USA) at 1,500 rcf for 2 min
to remove unbound biotin. Concentration of the antibody
and biotinylation efficiency were measured using a Nano-
Drop2000 instrument (Thermo Fisher Scientific, USA).
Optical densities (OD) values at 280 and 354 nm were
used to assess total protein and biotin concentrations, re-
spectively. Note that the biotinylation efficiency, estimated
here indirectly via ChromaLink measurements, varies be-
tween antibodies due to the abundance of Lysine residues.
For the conjugations performed in this experiment, we
found an up to 3-fold difference between individual anti-
bodies. The presence of aggregated antibody was assessed
at 450 nm. All values obtained in our experiments were
below 0.01 (The supplier recommends OD value <0.1 as
acceptable). Biotinylated antibodies were stored at 4 °C at
a concentration of 500 nM in PBS with 0.05 % NaN3 and
0.1 % Tween-20.
Acceptor-bead coupling of antibodies: 0.3 mg (for anti-
body screening) or 2 mg (for frequently used batches) of
Europium Acceptor-beads (AlphaLISA® Acceptor-beads,
PerkinElmer, USA) or Terbium Acceptor-beads (Alpha-
Plex™ 545 Acceptor-beads, PerkinElmer, USA) were washed
with PBS, centrifuged at 16,000 rcf for 15 min and re-
suspended in a 10:1 bead to antibody weight ratio. The vol-
ume was adjusted to 60 μl or 400 μl, respectively, with
0.13 M phosphate buffer pH 8.0. 10 % Tween-20 was added
to reach a final concentration of 0.06 % and freshly pre-
pared 25 mg/ml NaBH3CN in H2O to reach a final concen-
tration of 1.18 mg/ml. Afterwards the antibody-bead
solution was incubated for 48 h at 37 °C. To block
unreacted sites freshly made 65 mg/mL CMO in a 0.8 M
NaOH was added at a final concentration of 3 mg/ml and
incubated for 1 h at 37 °C. The antibody-bead solution was
centrifuged for 15 min at 16,000 rcf and washed twice with
60 μl or 400 μl, respectively, of 0.1 M Tris-HCl pH 8.0.
Antibody-coupled Acceptor-beads were re-suspended at
5 mg/mL in storage buffer (PBS + 0.05 % Proclin-300), vor-
texed, briefly sonicated (5 min in Branson1210 sonication
water bath) and stored at 4 °C.
In all steps below, antibodies and beads were diluted
in 1× assay buffer (10× AlphaLISA Immunoassay buffer:
250 mM HEPES, pH 7.4, 1 % Casein, 10 mg/mL
Dextran-500, 5 % Triton X-100 and 0.5 % Proclin-300,
PerkinElmer, USA) and samples were diluted using
PBS pH 7.4.
To screen antibody pairs for the h-asyn specific assay, a
fixed concentration of 100 μg/ml h-asyn overexpressing
rat brain lysate was used as a positive control. As negative
control (background) 100 μg/ml wild-type rat brain lysate
was used. For the pS129 h-asyn specific assay, a final con-
centration of 14 ng/ml pS129 h-asyn or 50 ng/ml S129A
h-asyn protein standard was added to 10 μg/ml asyn
knockout mouse brain lysate (matrix) and used as positive
and negative analyte, respectively. Each biotinylated anti-
body was combined with each Europium Acceptor-bead
coupled antibody.
Uniplex AlphaLISA optimization
Hook-point of biotinylated antibodies was determined
by serially diluting the biotinylated antibody 1:3 with a
50 μg/ml Europium Acceptor-bead solution resulting in
seven in-well dilutions ranging from 10 to 0.01 nM. To
10 μg/ml asyn knockout mouse brain lysate, 50 ng/ml of
h-asyn protein as a positive analyte or mouse asyn pro-
tein as a negative analyte (background) was added. For
the pS129 h-asyn specific assay, 14 ng/ml of pS129 h-
asyn protein was used as positive analyte or S129A h-
asyn protein as negative analyte (background) and spiked
into 10 μg/ml asyn knockout mouse brain lysate. Donor-
beads (AlphaScreen® streptavidin-coated Donor-beads,
PerkinElmer, USA) were added at a final concentration of
40 μg/ml.
Assay run protocol: 5 μl of sample were added into a
384-well AlphaPlate (PerkinElmer, USA). Each sample
was run in triplicate (except blanks which were run in
nine replicates) and a relative standard deviation be-
tween sample triplicates of <11 % and between blank
replicates of <21 % was accepted. A concentration of
50 μg/ml Europium Acceptor-beads coupled to anti-
bodies (1:100 dilution from stock) and 5 nM biotinylated
antibody (1:100 dilution from stock; except for hook-
point analysis) were mixed together beforehand and 5 μl
were added to each well. After 1 h of incubation in the
dark, 15 μl of Donor-beads (AlphaScreen® streptavidin-
coated Donor-beads, PerkinElmer, USA) at a concentra-
tion of 66.7 μg/ml (1:75 dilution from stock; except for
Donor-bead optimization) were added to each well.
All pipetting steps were done using the Janus pipetting
robot (PerkinElmer, USA). After an incubation of 30 min
in the dark, the plate was read using the EnVision 2104
Multilabel plate reader (PerkinElmer, USA). The standard
AlphaScreen emission filter (CW 570 nm) was used for
single emission assays.
Standard curves were established by serially diluting the
stock of recombinant proteins (1.9 μg/ml for h-asyn pro-
tein, 1.4 μg/ml for pS129 h-asyn and 5 μg/ml for remaining
recombinant proteins) 1:3 using 10 μg/ml rodent brain lys-
ate resulting in 11 dilutions ranging from 28 ng/ml to
0.28 pg/ml for pS129 h-asyn and 39.2 ng/ml to 0.39 pg/ml
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for h-asyn in-well synuclein concentration. Un-spiked ly-
sates were used as blanks and were run in nine replicates.
Duplex AlphaLISA optimization
Both Europium Acceptor-beads (AlphaLISA® Acceptor-
beads, PerkinElmer, USA) or Terbium beads (AlphaPlex™
545 Acceptor-beads, PerkinElmer, USA) were used to
develop a duplexing assay. Each signal measurement was
corrected for filter bleed-through. Hook-point was estab-
lished as described above.
Assay run protocol was modified so 50 μg/ml Europium
Acceptor-beads coupled to antibodies as well as 50 μg/ml
Terbium Acceptor-beads coupled to antibodies (for both
1:100 dilution from stock) and 5nM biotinylated antibody
(1:100 dilution from stock; except for hook-point analysis)
were mixed together beforehand and 5 μl were added to
each well. All pipetting steps were done using the Janus
pipetting robot (PerkinElmer, USA). A relative standard
deviation between sample triplicates for Europium chan-
nel of <13 % and for Terbium channel of <27 % was
accepted. Relative standard deviation between blank repli-
cates for Europium channel <19 % and for Terbium chan-
nel of ≤40 % was accepted. The plates were read using
first the Resorufine/Amplex Red FP535 filter for Terbium
signal and then again using the Europium 615 filters for
the Europium emission.
Standard curves were acquired by serially diluting the
stock of recombinant proteins (1.9 μg/ml for h-asyn pro-
tein, 1.4 μg/ml for pS129 h-asyn and 5 μg/ml for remaining
recombinant proteins) 1:2 using either 10 μg/ml rodent
brain lysate or appropriate dilutions of un-treated HEK293
cell lysates resulting in 11 or 18 dilutions ranging from
100 ng/ml to either 0.21 pg/ml in-well asyn concentration.
Un-spiked lysates were used as blanks and were run in nine
replicates.
Donor-bead optimization for duplexing assay was
achieved by serially diluting the Donor-beads with 1×
assay buffer to 4 different concentrations (200, 130, 70
and 30 μg/ml). As positive analyte 14 ng/ml of pS129 h-
asyn protein or as negative analyte mouse asyn protein
(background) was spiked into 10 μg/ml asyn knockout
mouse brain lysate.
Steric hindrance and filter bleed-through for duplexing
assay was tested by adding either PBS or 11A5 coupled
Europium Acceptor-beads (50 μg/ml final concentration)
to a stock solution containing 5 nM biotinylated 4B12
and 50 μg/ml LB509 coupled Terbium Acceptor-bead
and vice versa. As analyte 14 ng/ml of pS129 h-asyn pro-
tein was added to 10 μg/ml asyn knockout mouse brain
lysate. Un-spiked lysate was used as blank.
Recombinant alpha-synuclein protein standards
Glutathione S-transferase (GST)-tagged recombinant h-
asyn was obtained from MyBioSource, USA (MBS957854).
The remaining recombinant protein standards – pS129
h-asyn, S129A h-asyn and m-asyn were produced as
described below.
For pS129 h-asyn
Recombinant protein was produced as described elsewhere
[22, 44, 45]. Briefly, the pGEX-4T1 vector containing a
GST h-asyn fusion gene was inserted into E.coli BL-21 bac-
teria for protein expression. The transformed bacteria were
grown in Luria Bertani (LB) medium. Glutathione seph-
arose 4B beads were used to capture the GST h-asyn
proteins in the bacterial lysate and the GST-tag was
cleaved by thrombin. The molecular weight and purity
of the h-asyn proteins were confirmed by SDS-PAGE
gel and the concentration estimated using a BCA protein
assay (Pierce Biotechnology, Rockford, IL).
Purified h-asyn was phosphorylated at S129 in vitro by
adding 1 μg PLK2 protein to 1.44 mg/ml (100 μM) h-
asyn in kinase reaction buffer (20 mM HEPES, 1.09 mM
ATP, 2 mM DTT, 10 mM MgCl2, pH 7.4). Reaction
mixture was incubated at 30 °C for 24 h. Phosphoryl-
ation efficiency of h-asyn was determined by loading
300 ng protein on isoelectric focusing gels pH5-8
(Bio-Rad, USA) to separate pS129 h-asyn from non-
phosphorylated h-asyn by charge. Gels were ran for
30 min at 100 V, 30 min at 250 V and 1.5 h at 500 V and
afterwards incubated in Western Blot (WB) running buf-
fer (25 mM Tris, 192 mM Glycine, 0.1 % SDS) for 15 min
to ensure blotting of proteins on PVDF membranes using
the Trans-Blot Turbo transfer system (Bio-Rad, USA).
Membrane was then blocked using 5 % milk in 0.01 %
Tween in tris-buffered saline (TBS-T) buffer (5 mM Tris,
15 mM NaCl) followed by incubation in primary antibody
(syn-1 1:2,000, BD Biosciences, UK; 11A5 1:5,000, Prothena
Biosciences Inc.) in 2 % milk in TBS-T at 4 °C over night.
After washing membranes 3x 10min with TBS-T, secondary
goat anti mouse antibody (Santa Cruz, USA) was incubated
at 1:10,000 in 2 % milk in TBS-T for 1 h. Membranes were
rinsed withTBS-T, incubated in an ECL mix of 1:1 peroxide
to luminol solution (Clarity Western ECL Substrate, Bio-
Rad, USA) and placed into the ChemiDoc Imaging system
(Bio-Rad, USA).
For m-asyn
The expression and purification was carried out as de-
scribed previously [46]. Briefly, bacterial expression vec-
tor pRK172 containing m-asyn gene (kindly provided by
Virginia Lee’s laboratory, Institute on Aging and Center
for Neurodegenerative Disease Research, University of
Pennsylvania, Philadelphia, USA) was inserted into E.coli
BL-21 bacteria for protein expression and grown using
TB media. Spun down bacterial pellets were then re-
suspended in high-salt lysis buffer (750 mM NaCl,
100 mM MES, 1 mM EDTA, pH 7.0) containing
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protease inhibitors. The lysate was then heated to 100 °C
for 10 min and centrifuged at 10,000×g for 30 min. The
supernatant was dialyzed against 10 mM Tris at pH 7.5
and applied first to a size exclusion column (Superdex
200) followed by a Mono Q column.
For S129A h-asyn
The pT7-7 vector containing the S129A h-asyn gene
was kindly provided by Hilal Lashuel’s laboratory
(Brain Mind Institute, Ecole Polytechnique Federale
de Lausanne). The vector was inserted in E-Coli BL-21
bacteria and grown in LB media. The bacterial lysate
was subjected to gel filtration purification using Superdex
200 chromatography column, followed by anion exchange
purification by Mono-Q column.
Animals
C57/Bl6-OlaHsd mice - lacking the asyn gene - were ob-
tained from Harlan (Kentucky, USA) and young adult
female Sprague Dawley rats (200–225 g) obtained from
Charles River (Kisslegg, Germany). Animals were housed
with ad libitum access to food and water on a 12 h light-
dark cycle. All experimental procedures were approved
by the Ethical Committee for Use of Laboratory Animals
in the Lund-Malmö region.
Rat brain samples overexpressing h-asyn were ob-
tained in a separate study (Landeck et al., unpublished
data). Briefly, neonatal Sprague Dawley rat pups were
injected with rAAV5 vectors expressing h-asyn into the
dorsal striatum. Twelve months after injection, frontal
brain area was dissected and stored at -80 °C for further
analysis. Samples were used for evaluation of antibodies
on western blot and assay screening only.
Preparation of tissue matrix used for Western blot and
recombinant protein spiking
Brain tissue samples for WB analysis and recombinant
protein spiking were extracted using a ratio of 1:5 weight
per volume of Tris lysis buffer (144 mM NaCl, 50 mM
Tris, 2 mM EDTA, pH 7.6) or Tris buffer containing
1 % SDS. Protease and Phosphatase inhibitors (Roche,
Switzerland) were added to buffers before use. Tissue
was lysed using a probe sonicator (Sonics & materials,
USA) 10× 2 s at 40 Hz, incubated on ice for 15 min and
centrifuged for 10 min at 21,000 rcf at 4 °C. Supernatant
was transferred to a new tube. Protein concentration
was determined using the DC protein assay kit (Bio-Rad,
USA) and samples were stored at -80 °C.
Western blot analysis for determination of antibody
specificity
Protein lysate (50 μg for asyn specific antibodies or
100 μg pS129 asyn specific antibodies) and recombinant
protein (2 ng) were separated on SDS-polyacrylamide gels
with an 8–16 % gradient (Bio-Rad, USA) and trans-
ferred onto PVDF membranes using the Trans-Blot
Turbo transfer system (Bio-Rad, USA). The membranes
were incubated with 5 % milk in TBS-T buffer for 1 h at
room temperature (RT) to block unspecific binding. Pri-
mary antibodies were added at a concentration of 0.2 μg/
ml for asyn specific antibodies, 1 μg/ml for pS129 asyn
specific antibodies or 1:200 dilution for EP1536Y and
pSyn#64 in 2 % milk in TBS-T and incubated over night at
4 °C. The next day the membranes were washed with
TBS-T and the appropriate peroxidase-coupled secondary
antibody (Santa Cruz, USA) at 1:10,000 was added in 2 %
milk in TBS-T for 1 h. After rinsing with TBS-T the mem-
branes were incubated in an ECL mix of 1:1 peroxide to
luminol solution (Clarity Western ECL Substrate, Bio-
Rad, USA) and placed into the ChemiDoc Imaging system
(Bio-Rad, USA).
HEK293 cell transfection and lysis
PEI solution was prepared by dissolving Polyethylenei-
mine (Polysciences, USA) using 80 °C warm H2O to
reach a concentration of 1 g/l. Solution was let cool
to RT, pH was set to 7.0 by adding HCl, H2O was
added to reach final concentration and solution was
filtered sterile using a 0.22 μm membrane. Aliquots
were stored at -20 °C. On the day of transfection PEI
solution was thawed in a 37 °C water bath. 1 μg
DNA in total and 3 μg PEI (added last) in 100 μl
were used per ml culture medium, mixed by vortex-
ing, incubated at RT for 15 min and added to cell
culture at a confluency of 75–90 % on a 6-well plate.
48 h later cells were collected in 1 ml of PBS, trans-
ferred to a tube and spun down at 200 rcf for 5 min.
Supernatant was discarded and 100 μl of lysis buffer
[1 % SDS, 144 mM NaCl, 50 mM Tris, 2 mM EDTA,
pH 7.6, protease and phosphatase inhibitors (Roche,
Switzerland)] was added to the cell pellet. Cells were
then sonicated (10× 2 s at 40Hz), the solution was in-
cubated on ice for 15 min and then centrifuged at
21,000×g for 15 min at 4 °C. Supernatant was trans-
ferred to a new tube, protein concentration deter-
mined using the DC protein assay kit (Bio-Rad, USA)
and samples stored at -80 °C. Samples were diluted
1:10 in PBS before run on the assay.
Production of viral vectors
Recombinant adeno-associated viral vectors serotype 6
(rAAV6) contained a synapsin1 promoter (syn1) express-
ing either h-asyn, polo-like kinase 2 (PLK2), a PLK2
dead mutant (mPLK2) or GFP followed by a h-SV40
polyA sequence. These cassettes were flanked by inverted
terminal repeats (ITR2). HEK293 cells at 70–80 % conflu-
ence were co-transfected using the calcium-phosphate
precipitation method including the rAAV plasmid and
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helper as previously described [47]. After 3 days of incuba-
tion, cells were harvested and lysed by performing three
freeze-thaw cycles in a dry ice/ethanol bath. After treat-
ment with benzonase (Sigma-Aldrich, Sweden) the lysate
was purified using a discontinuous iodixanol gradient
followed by Separose Q column chromatography [48] and
then concentrated with a 100kD cut-off column (Millipore
Amicon Ultra, Millipore, Sweden). To determine the titer
of the viral vector solutions quantitative PCR with probes
targeting the ITR sequence was performed. Prior to use in
experiments, vectors were mixed 1:1 and diluted using
PBS to a concentration of 5E13 gc/ml per vector (1E14
gc/ml per vector mix) and re-titered.
Animals and stereotaxic surgery
Young adult Sprague Dawley rats were anesthetized by
i.p. injection of 6 ml/kg of a 20:1 mixture of Fentanyl
and Dormitor (Apoteksbolaget, Sweden). After placing
the animal into a stereotaxic frame (Stoelting, USA),
2 μl of rAAV6 vector solution was injected into the
right SN using the following coordinates: anteroposter-
ior (AP) -5.0 mm, mediolateral (ML) -2.0 mm from
bregma and dorsoventral (DV) -7.2 mm from the dura.
The tooth bar was adjusted to -2.3 mm. 2 μl of vector
was deposited into the left striatum using the following
coordinates: AP +1.0 mm, ML +3.0 mm from bregma
and DV -5.0 mm from the dura. The tooth bar was ad-
justed to 0.0 mm. Injection was performed using a
pulled and cut glass capillary (final outer diameter of
about 60–80 μm) attached onto a 5 μl Hamilton syringe
with a 22 s gauge needle. After delivery of the viral
vector using a pulsed injection of 0.1 μl every 15 s, the
capillary was held in place for 5 min, retracted 0.2 mm
and after 1 min it was slowly withdrawn from the brain.
Temgesic and Antisedan (Apoteksbolaget, Sweden) were
administered s.c. as analgesic treatment and to reverse
anesthesia, respectively.
Rat brain tissue lysis
Dissected and fresh frozen brain tissue samples were se-
quentially lysed 200 mg/ml in first Triton lysis buffer
[150 mM NaCl, 50 mM Tris pH 7.6, 1 % Triton X-100,
2 mM EDTA containing protease and phosphatase in-
hibitors (Roche, Switzerland)] by sonication 15× for 1 s.
Ipsilateral striatum to ventral midbrain injected brains
were sequentially lysed in first 20 mM Tris-acetate buf-
fer (TAE) pH 6.1, sonicated 15× for 1 s, 80 μl of each
brain lysate were transferred to a new tube and 9 μl of
10 % Triton containing 10× protease and phosphatase
inhibitors added. After incubation for 10 min on ice, all
samples were centrifuged at 21,000 rcf for 10 min at 4 °
C and supernatant transferred to new tubes. Lysing step
was repeated two more times, supernatant from all lys-
ing steps for each brain were collected in one single
tube, termed here Triton fraction. Leftover pellet was
lysed in SDS lysis buffer (150 mM NaCl, 50 mM Tris
pH 7.6, 1 % SDS, 2 mM EDTA containing protease
and phosphatase inhibitors) twice by repeating steps de-
scribed above at RT. Both supernatants were combined
in one tube for each brain, termed here the SDS frac-
tion and contain a fraction of proteins in the samples
that are either resistant to Triton solubilization or lo-
cated within the nucleus. Protein concentration of each
fraction was determined using the DC™ protein assay
kit (Bio-Rad, USA). Triton fractions were diluted 1:300
for ventral midbrain and 1:100 for striatal samples be-
fore running them on the AlphaLISA duplex assay
while SDS fractions were diluted 1:10.
Rat brain histological analysis
Animals were killed at 2 weeks after vector treatment by so-
dium pentobarbital (Apoteksbolaget, Sweden) and perfused
with 50 ml of 0.9 % NaCl followed by 250 ml of ice-cold 4 %
paraformaldehyde (PFA in 0.1 M phosphate buffer, pH7.4)
for 5 min. Brains were removed, post-fixed in 4 % PFA for
24 h and then transferred into 25 % sucrose. Then brains
were cut using a semi-automated freezing microtome
(Microm HM 450) into 35 μm thick coronal sections
and stored in antifreeze solution (0.5 M phosphate buf-
fer, 30 % glycerol, 30 % ethylene glycol) at -20 °C.
Histological processing was performed using an im-
munohistochemical staining protocol on free-floating
sections. Brain sections were washed using TBS. To
quench the endogenous peroxidase activity sections were
incubated in 3 % H2O2 and 10 % methanol in TBS buffer
for 30 min. After 3 washes with TBS buffer, sections
were incubated for 30 min in 0.05 % Triton X-100 in
TBS buffer (TBS-T) containing 5 % normal serum from
the same species the secondary antibody was raised in.
The primary antibody asyn211 (1:100,000) was applied
in 1 % BSA in TBS-T over night at RT. The next day
sections were rinsed with TBS-T and incubated with
horse anti mouse biotinylated secondary antibody (1:200,
Vector Laboratories Inc.) in 1 % BSA in TBS-T for 1 h.
Sections were again washed with TBS-T and incubated
with an avidin-biotin-peroxidase complex solution
(Vectastain ABC kit, Vector Laboratories Inc., USA) for
1 h. The specific staining was visualized using 3,3′-di-
aminobenzidine (DAB Safe, Saveen Werner, Sweden)
and 0.01 % H2O2. For preservation and visualization,
sections were mounted on chromatin-gelatin coated
glass slides, dried, dehydrated in increasing alcohol so-
lutions, cleared in xylene and coverslipped using DPX
(Sigma-Aldrich, Sweden).
For double labeling of h-asyn and PLK2, sections
were washed using KPBS (3.4 mM KH2PO4, 15.3 mM
K2HPO4, 145 mM NaCl) and incubated in Tris/EDTA
buffer (10 mM Tris, 1 mM EDTA, pH 9) at 80 °C for
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30 min. After letting the sections cool down for
20 min, specimens were washed with KPBS and incu-
bated in 0.25 % Triton in KPBS containing 5 % nor-
mal serum from same species the secondary antibody
was raised in. Then, the primary antibodies asyn211
(1:10,000) and PLK2 (1:200, sc-25421, Santa Cruz,
USA) were added and incubated over night at RT.
The next day sections were rinsed with KPBS and in-
cubated in 0.25 % Triton + 5 % normal serum in
KPBS for 1 h containing secondary antibody biotinyl-
ated goat anti rabbit (1:200, Vector Laboratories Inc.,
USA). Sections were again washed with KPBS and in-
cubated with 0.25 % triton + 5 % normal serum in KPBS
containing AlexaFluor647 conjugated streptavidin (1:200,
Invitrogen, USA) and secondary antibody donkey anti
mouse coupled to AlexaFluor488 fluorophore (Jack-
son, USA) for 2 h. After washes with KPBS, sections
were mounted and coverslipped using PVA-DABCO
mounting medium (Sigma-Aldrich, Sweden). Confocal im-
ages were taken using a Nikon eclipse Ti inverted micro-
scope with a 60× oil lens and the Nikon D-eclipse C1
detector.
For cresyl violet staining, sections were mounted on
chromatin-gelatin coated glass slides and dried overnight,
hydrated in decreasing alcohol solutions and stained for
30 s in 0.5 % cresyl violet (Sigma-Aldrich, Sweden) +
0.1 % acidic acid. After a wash in H2O, sections were
dehydrated in increasing alcohol solutions, cleared in xy-
lene and coverslipped using DPX.
Densitometry
Staining intensity of DARPP32- and VMAT2-possitive
neurons was measured on digital images taken from
coronal striatal and ventral midbrain sections, respect-
ively, using the Zeiss microscope (Axio Zoom.V16,
Zeiss, Germany). Every 24th section of the striatum
and every 12th section of the ventral midbrain in the
rostro-caudal axis was outlined using ImageJ and op-
tical density readings were corrected for non-specific
background using density measurements from the
corpus callosum or dorsal midbrain of each animal.
Human tissue processing and analysis
Human brain tissues were obtained from the Sydney Brain
Bank at Neuroscience Research Australia. Standardized
clinicopathological criteria were used for diagnosis [49]
with dementia status and severity determined using the
Clinical Dementia Rating (CDR) scale [50]. Parkinson’s
disease (PD) cases fulfilled the UK PD Society Brain Bank
Diagnostics Criteria [51] and did not have any mutations
correlated with PD. Controls (Ctrl) had no significant
neuropathology and no evidence of neurological or psy-
chiatric disease. Ethics approval for this study was ob-
tained from the Human Research Ethics Committee at the
University of New South Wales. Demographic details for
each group are listed as median (interquartile range): The
age range of cases (n = 16) used for assay reproducibility
tests was 74 (22) years, for Ctrl group (n = 8) was 90 (6)
years, for PD group (n = 8) was 82 (10.5) years and for
PDD group (n = 8) was 81 (7) years. The onset as well as
duration of PD was 64 (9) and 17 (6) years for PD group,
and 67 (8) and 15 (3) years for PDD group, respectively.
The duration of dementia for the PDD group was 3.5 (2)
years. Post-mortem interval for the cases used for repro-
ducibility testing was 29 (19) hours, for Ctrl, PD and PDD
groups 23 (11), 18 (18) and 24 (23) hours.
Tissue samples from the Ctrl, PD and PDD cohorts
were homogenized 200 mg/ml in 20 mM Tris-acetate
(TAE) buffer pH 6.1 using stainless steel beads and a Tis-
suelyser II system (Qiagen) at 20 Hz for 40 s. Enzymatic
analysis of the same cohort of samples was performed
earlier [42]. Lysate (150 μl) was transferred to a new tube,
16 μl of 10 % Triton containing 10× protease and phos-
phatase inhibitors (Roche, Switzerland) added (for se-
quential extraction) and samples sonicated 10× 1 s at
40Hz. Tissue samples used for the reproducibility
testing were lysed in 20 mM TAE buffer pH 6.1 and
sonicated 10x for 1 s at 40 Hz. After incubation on
ice for 10 min and centrifugation for 10 min at
21,000 rcf and 4 °C, supernatant was transferred to a
new tube and lysing step repeated twice more using
60 μl 1 % Triton in TAE buffer + inhibitors, superna-
tants were combined to a single tube, here referred to
as Triton fraction. Remaining pellet was again lysed
in two consecutive steps (as described above at RT)
in 75 μl of 1 % SDS in TAE buffer + inhibitors, both
supernatants were combined to a single tube, termed
here the SDS fraction. Protein concentration of each
fraction was determined using the DC™ protein assay kit
(Bio-Rad, USA). Triton fractions were diluted 1:300 before
running samples on the AlphaLISA duplex assay while
SDS fractions were diluted 1:10.
Data processing and statistical analysis
S/B ratio was calculated by dividing the ‘signal of analyte’
by the ‘signal of blank’. Hook-point values were calcu-
lated by subtracting the background signal from the
positive sample signal. The LDL was calculated as mean
of 9 blank replicates + 3*SD. Standard curve fitting was
done using the GraphPad Prism6 program. A sigmoid
weighted curve was fitted on signal measured and corre-
sponding log transformed asyn concentration values. A
fitting of R2 ≥90.5 % was accepted. Blanks were set to
1E-25 mg/ml. Intra and inter assay variations were de-
termined by calculating the concentration of a sample
containing a known amount of h-asyn using the fitted
model of a standard curve run on the same plate. Rela-
tive standard deviations of analyzed concentration values
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were calculated for matching samples run on the same
day or on different days. Sample reproducibility was
assessed by repeated measures for each of the 16 cases
over several days. Each repeated value is expressed as
percent of mean of all repeats. Z’ values were calculated
using the following equation:
Z’ ¼ 1–





Data is shown as mean ± standard error of the mean
(SEM). Statistical analysis was carried out using the
GraphPad Prism6 program (GraphPad Software, La Jolla,
CA, USA). For HEK293 and rat brain measurements, a
two-tailed Mann-Whitney test was used. Human data sets
were first tested for normal distribution using the D’Agos-
tino & Pearson omnibus normality test. Then either a
one-way ANOVA followed by a Tukey’s HSD test for
normally distributed measurements or a Kruskal-Wallis
followed by a Dunn’s multiple comparisons test was used.
Differences were considered significant for p <0.05.
Additional files
Additional file 1: Figure S1. Principle and protocol of the AlphaLISA
technique. In A Streptavidin-coated Donor-beads are bound to biotinylated
antibodies. Acceptor-beads are directly coupled to antibodies. When both
antibodies bind to an analyte, the beads are brought into close proximity.
Donor-beads are excited at 680 nm and produce singlet oxygen molecules
triggering a chemical reaction in the close-by Europium Acceptor-beads
resulting in an emission of light at 615 nm. In B the protocol of a no-wash
AlphaLISA is depicted. (PDF 315 kb)
Additional file 2: Figure S2. Quantification of S129 phosphorylation of
human alpha-synuclein recombinant protein. An isoelectric focusing gel
pH range 5–8 (A) was used to separate pS129 from non-phosphorylated
h-asyn by loading recombinant h-asyn and pS129 h-asyn protein side
by side. In B, blots were probed for total h-asyn (syn-1) or pS129 h-asyn
(11A5) to determine pS129 h-asyn band. Quantification areas are indicated
on total h-asyn blots by dashed boxes. This assay was run independently
on three occasions, which yielded estimates of percent phosphorylation of
h-asyn at S129 site to be 28.4, 29.5, and 26.0 %, respectively, with an average
and standard deviation of 28.0 ± 1.8 %. (PDF 339 kb)
Additional file 3: Figure S3. Scheme of AlphaLISA duplex assay for
total and S129 phosphorylated human alpha-synuclein detection. The
4B12 antibody – binding to aa 103–108 – is biotinylated and used to
bind the Streptavidin-coated Donor-beads. Terbium Acceptor-beads were
coupled to LB509 antibodies for total h-asyn quantification while the
11A5 antibody was used and attached to Europium Acceptor-beads in
order to measure pS129 h-asyn. Both antibodies recognize an epitope
close to each other (aa 115–122 and aa 129 respectively). (PDF 500 kb)
Additional file 4: Figure S4. Principle of steric hindrance analysis and
filter bleed-through. A hypothetical illustration of signal change caused
by a possible steric hindrance of 11A5-Europium (11A5-Eu) and LB509-
Terbium (LB509-Tb) molecules when being added together in one well
is depicted in A. At baseline (A1) no steric hindrance is possible since
only one Acceptor-bead coupled antibody is in solution, here shown for
Terbium Acceptor-beads. Adding the second antibody (in this case 11A5)
coupled to Europium Acceptor-beads can either result in signal reduction
(A2) or in similar emission intensity (A3). Hypothetical signal values are
illustrated in A’. Filter bleed-through for this assay protocol was determined
by four measurement conditions illustrated as examples in B1-B4. First
background signal for Terbium Acceptor-bead was established by
using the appropriate filter as well as by not adding any analyte or
Europium Acceptor-bead (B1). Background signal for Europium filter
was measured by using the same well (B3). Adding the analyte to
the above described mix will result in a corresponding signal when
the Terbium filter is used (B2) and in a false signal (X % of Terbium
signal) when the Europium filter is used (B4). Example of signals
(green for Terbium, red for Europium) and % calculations is illustrated
in B’. Same measurements and calculations were done for the Terbium
assay protocol. (PDF 528 kb)
Additional file 5: Figure S5. Assessment of optimal Donor-bead
concentration. The ideal Donor-bead concentration was determined
once simultaneously in a mix of Europium Acceptor-bead coupled
11A5 antibody and Terbium Acceptor-bead coupled LB509 antibody. Arrows
indicate optimal 4B12 concentrations for both Acceptor-bead variants. AU:
arbitrary units. (PDF 156 kb)
Additional file 5: Figure S6. Assessment of assay reproducibility in the
duplex assay using cortical human samples. Tissue samples of the frontal
cortex (n = 16) were lysed using buffer containing 1 % Triton and repeatedly
analyzed (n = 5) using the duplex assay for total and pS129 h-asyn
concentration on separate days. Percent variation from the mean
value for each sample is plotted for total h-asyn measurements (A),
for pS129 h-asyn (B) and for total to pS129 h-asyn ratio (C). Dashed
lines indicate ± 25 % variation while thin lines indicate ± 10 % variation from
mean (0 %). (PDF 233 kb)
Additional file 7: Figure S7. Endogenous rat total and S129
phosphorylated levels. Fresh frozen striatal and ventral midbrain tissue
samples of naïve rats were sequentially lysed in first 1 % Triton (A) then in
1 % SDS containing lysis buffer (B) and diluted 1:300 or 1:10, respectively.
Samples (n = 6 per region) were run on AlphaLISA uniplex assays using the
biotinylated syn-1 antibody (BD Biosciences, UK) combined with either 4D6
(Abcam, UK) or 11A5 (Prothena Biosciences Inc.) conjugated on the
Europium Acceptor-beads for the detection of total and pS129 asyn,
respectively. As reference protein, pS129 h-asyn was used for both
assays and spiked into appropriate asyn knockout mouse brain lysate.
Total (open) and pS129 (filled) r-asyn levels are presented in overlapping
bars. Numbers inside the bars show the percent of pS129 to total r-asyn.
Error bars indicate SEM. (PDF 173 kb)
Abbreviations
11A5-Eu, 11A5 antibody coupled to Europium Acceptor-beads; asyn, alpha-
synuclein; AU, arbitrary units; CSF, cerebrospinal fluid; Ctrl, control; h-asyn, hu-
man alpha-synuclein; k.o., knock out; LB509-Tb, LB509 antibody coupled to
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Parkinson’s disease; PDD, Parkinson’s disease with dementia; PLK2; Polo-like
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associated virus serotype 6; S/B, signal to background; SN, substantia nigra;
uninj., uninjected; WT, wild type
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